### Index

*Note: Page numbers of article titles are in **boldface** type.*

<table>
<thead>
<tr>
<th>A</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>“Abortion storms,”</td>
<td>363</td>
</tr>
<tr>
<td></td>
<td>Adult intestinal toxemia botulism,</td>
<td>317</td>
</tr>
<tr>
<td></td>
<td>Allergen Pharmaceuticals,</td>
<td>315</td>
</tr>
<tr>
<td></td>
<td>Alphaviruses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>as category B potential bioterrorism agent,</td>
<td>406–408</td>
</tr>
<tr>
<td></td>
<td>American Society for Microbiology,</td>
<td>195</td>
</tr>
<tr>
<td></td>
<td>Anthrax, <strong>227–251</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>clinical manifestations of,</td>
<td>237–240</td>
</tr>
<tr>
<td></td>
<td>cutaneous,</td>
<td>237</td>
</tr>
<tr>
<td></td>
<td>gastrointestinal,</td>
<td>237–238</td>
</tr>
<tr>
<td></td>
<td>genetics of,</td>
<td>231–234</td>
</tr>
<tr>
<td></td>
<td>hemorrhagic meningencephalitis,</td>
<td>238–239</td>
</tr>
<tr>
<td></td>
<td>history of,</td>
<td>229–231</td>
</tr>
<tr>
<td></td>
<td>inhalational victims of recognition of,</td>
<td>234–236</td>
</tr>
<tr>
<td></td>
<td>microbiologic diagnosis of,</td>
<td>239–240</td>
</tr>
<tr>
<td></td>
<td>microbiology of,</td>
<td>231–234</td>
</tr>
<tr>
<td></td>
<td>pathogenesis of,</td>
<td>232–234</td>
</tr>
<tr>
<td></td>
<td>prevention of postexposure,</td>
<td>242–246</td>
</tr>
<tr>
<td></td>
<td>treatment of,</td>
<td>240–246</td>
</tr>
<tr>
<td></td>
<td>current,</td>
<td>240–242</td>
</tr>
<tr>
<td></td>
<td>decontamination in,</td>
<td>244–246</td>
</tr>
<tr>
<td></td>
<td>emerging therapies in,</td>
<td>242</td>
</tr>
<tr>
<td></td>
<td>human vaccination in,</td>
<td>242–243</td>
</tr>
<tr>
<td></td>
<td>infection control in,</td>
<td>244–246</td>
</tr>
<tr>
<td></td>
<td>investigational therapies in,</td>
<td>242</td>
</tr>
<tr>
<td></td>
<td>vaccines in,</td>
<td>243–244</td>
</tr>
<tr>
<td></td>
<td>virulence factors in,</td>
<td>232–234</td>
</tr>
<tr>
<td></td>
<td>Antibiotic(s)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in plague prevention,</td>
<td>284</td>
</tr>
<tr>
<td></td>
<td>Antonine plague,</td>
<td>260–262</td>
</tr>
<tr>
<td></td>
<td>Galen’s description of,</td>
<td>261–262</td>
</tr>
<tr>
<td></td>
<td>historical background of,</td>
<td>260–261</td>
</tr>
<tr>
<td></td>
<td>Arenaviridae</td>
<td></td>
</tr>
<tr>
<td></td>
<td>clinical presentation and management of,</td>
<td>370–375</td>
</tr>
<tr>
<td></td>
<td>Arenaviruses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>virology and pathology of,</td>
<td>360–362</td>
</tr>
<tr>
<td></td>
<td>Argentine hemorrhagic fever clinical presentation and management of,</td>
<td>373–374</td>
</tr>
<tr>
<td></td>
<td>Avian influenza as category C potential bioterrorism agent,</td>
<td>430–432</td>
</tr>
<tr>
<td></td>
<td>Bacteria</td>
<td></td>
</tr>
<tr>
<td></td>
<td>as category B potential bioterrorism agent,</td>
<td>410–412</td>
</tr>
<tr>
<td></td>
<td>Biologic agents</td>
<td></td>
</tr>
<tr>
<td></td>
<td>deliberate release of recognition of,</td>
<td>219–220</td>
</tr>
<tr>
<td></td>
<td>suddenness of,</td>
<td>219–220</td>
</tr>
<tr>
<td></td>
<td>unusual clinical presentation of,</td>
<td>220</td>
</tr>
<tr>
<td></td>
<td>unusual geographic, temporal, or demographic clustering in,</td>
<td>220</td>
</tr>
<tr>
<td></td>
<td>Biologic weapons plaque as,</td>
<td>279–280</td>
</tr>
<tr>
<td></td>
<td>Biological warfare plague-related historical aspects of,</td>
<td>269–271</td>
</tr>
<tr>
<td></td>
<td>Biological weapons system components of,</td>
<td>184–185</td>
</tr>
<tr>
<td></td>
<td>BioSense</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in syndromic surveillance of bioterrorism agents,</td>
<td>222</td>
</tr>
<tr>
<td></td>
<td>Bioterrorism, <strong>179–211</strong>. See also Bioterrorism preparedness. anthrax in,</td>
<td><strong>227–251</strong>. See also Anthrax. defined,</td>
</tr>
<tr>
<td></td>
<td>historical perspective of,</td>
<td>180–184</td>
</tr>
<tr>
<td></td>
<td>postbacterial cultivation era,</td>
<td>181–182</td>
</tr>
<tr>
<td></td>
<td>post–World War I era,</td>
<td>182–184</td>
</tr>
<tr>
<td></td>
<td>prebacterial cultivation era,</td>
<td>180–181</td>
</tr>
</tbody>
</table>

0891-5520/06/$ - see front matter © 2006 Elsevier Inc. All rights reserved. doi:10.1016/S0891-5520(06)00050-X
Bioterrorism agents, 206–208, 213–225
biologic agents
deliberate release of recognition of, 219–220
infectious diseases as surveillance of, 216–218
potential category B, 395–421. See also Category B potential bioterrorism agents.
category C, 423–441. See also Category C potential bioterrorism agents.
Bioterrorism preparedness and response microbial forensics in, 455–473. See also Microbial forensics.
Bioterrorism preparedness program backbone of elements of daily practice in, 447–448 communication in ensurance of appropriate internal and external mechanisms of, 448–449 community preparedness in emphasis on, 452 dissemination of, 447 ensurance of familiarity by all key stakeholders in, 447 feasibility and viability of assessment of, 446–447 improving collaboration with community physicians, area hospitals, and local health departments in, 451–452 in hospital setting implementation of practical aspects of, 443–453 intensified surveillance of incorporation of internal mechanisms for, 448 key components of building redundancy for, 450 incorporation of flexibility in, 450 periodical testing of drills for, 449–450 surge capacity in addressing logistics involving, 450–451 written plan, 444–446
Bioterrorism weapons smallpox as, 329–357. See also Smallpox.
Bolivian hemorrhagic fever, 374
Brucella sp as category B potential bioterrorism agents, 397–398
Bubonic plague, 255
INDEX 477

Bunyavirus(es)
  as category B potential bioterrorism agent, 408

Bunyavirus genus
  clinical presentation and management of, 375
  virology and pathology of, 362

Burkholderia sp
  as category B potential bioterrorism agent, 398–400
    B mallei, 398–400
    B pseudomallei, 398–400

C
  Campylobacter jejuni
    as category B potential bioterrorism agent, 411

Category B potential bioterrorism agents, 395–421
  alphaviruses, 406–408
  Brucella sp, 397–398
  bunyaviruses, 408
  Burkholderia sp
    B mallei, 398–400
    B pseudomallei, 398–400
  Chlamydia psittaci, 400–401
  Coxiella burnetti, 401–402
  described, 395
  EEE, 406–408
  epsilon toxin of Clostridium perfringens, 403–404
  flaviviruses, 408–410
  foodborne and waterborne pathogens, 410–415
  bacteria, 410–412
  protozoa, 413–414
  viruses, 412–413
  ricin, 404–405
  Rickettsia prowazekii, 402–403
  staphylococcal enterotoxin B, 405–406
  types of, 396
  VEE, 406–408
  WEE, 406–408

Category C potential bioterrorism agents, 423–441
  avian influenza, 430–432
  described, 423
  emerging pathogens, 430–436
  genetically engineered biologic weapons, 436
  hantaviruses, 425–426
  monkeypox virus, 434–436
  multidrug-resistant tuberculosis, 430
  Nipah virus, 423–424
  pandemics of influenza, 430–432
  SARS, 432–433
  tick-borne encephalitis complex, 427–428
  tick-borne hemorrhagic fever viruses, 428–429
  West Nile virus, 433–434
  yellow fever virus, 426–427

Centers for Disease Control and Prevention (CDC), 179, 213, 395, 468
  in smallpox diagnosis, 339

Chickenpox
  smallpox vs, 340–341

Chlamydia psittaci
  as category B potential bioterrorism agent, 400–401

Chordopoxvirinae, 329–330

Clostridium botulinum
  botulism due to, 315

Clostridium perfringens
  epsilon toxin of
    as category B potential bioterrorism agent, 403–404

Congo-Crimean hemorrhagic fever
  clinical presentation and management of, 376–377

Coxiella burnetti
  as category B potential bioterrorism agent, 401–402

Cryptosporidium parvum
  as category B potential bioterrorism agent, 413

Cutaneous anthrax, 237

Cyclospora cayetanensis
  as category B potential bioterrorism agent, 413

D
  Decontamination
    in anthrax prevention, 244–246

Dengue fever
  clinical presentation and management of, 381–383

Dengue virus
  virology and pathology of, 367–368

Department of Defense, 195, 347

Department of Health and Human Services, 347
INDEX

E

Eastern equine encephalitis (EEE)
  as category B potential bioterrorism agent, 406–408

Ebola virus
  clinical presentation and management of, 379–381
  virology and pathology of, 366–367

EEE. See Eastern equine encephalitis (EEE).

Electronic Surveillance System for the Early Notification of Community-based Epidemics (ESSENCE) in syndromic surveillance of bioterrorism agents, 222

Encephalitis
  smallpox vaccination and, 343–344

Encephalopathy
  smallpox and, 339

Endemic disease. See also Viral hemorrhagic fevers.
  current status of, 359–393
  strategies for control of, 359–393

Entamoeba histolytica
  as category B potential bioterrorism agent, 413

Enterocytozoon bieneusi
  as category B potential bioterrorism agent, 414

Entomopoxvirinae, 329

Epidemiology studies
  in microbial forensics, 457–459

Epsilon toxin of Clostridium perfringens
  as category B potential bioterrorism agent, 403–404

Escherichia coli
  as category B potential bioterrorism agent, 411

ESSENCE. See Electronic Surveillance System for the Early Notification of Community-based Epidemics (ESSENCE).

Exzema vaccinatum
  smallpox vaccination and, 344–345

F

FBI, 468

Fever(s). See also specific types, eg, Lassa fever.

hemorrhagic viral, 359–393. See also Viral hemorrhagic fevers.

Filoviridae
  clinical presentation and management of, 379–381
  virology and pathology of, 366–367

Flaviviridae
  clinical presentation and management of, 381–384
  virology and pathology of, 367–369

Flavivirus(es)
  as category B potential bioterrorism agent, 408–410

Florida Department of Health, 455

Fogarty International Center, 196

Foodborne botulism, 316–317

Foodborne contamination intentional botulinum toxin and, 321

Forensics
  microbial, 455–473. See also Microbial forensics.

Francisella tularensis
  as potential bioterrorism agent, 304–305

G

Gastrointestinal anthrax, 237–238

Genetic(s)
  of anthrax, 231–234

Genetically engineered biologic weapons
  as category C potential bioterrorism agent, 436

Giardia lamblia
  as category B potential bioterrorism agent, 413

Glandular tularemia, 297–299

Global Outbreak Alert and Response Network, 196–197

Guanarito virus
  clinical presentation and management of, 373

H

Hantavirus(es)
  as category C potential bioterrorism agent, 425–426
Hantavirus genus
clinical presentation and management of, 377–379
virology and pathology of, 364–366
Harvard Medical School, 333
Hemorrhagic fever(s)
viral, 359–393. See also Viral hemorrhagic fevers.
Hemorrhagic fever viruses
tick-borne
as category C potential bioterrorism agent, 428–429
Hemorrhagic meningoencephalitis, 238–239
Hepatitis A virus
as category B potential bioterrorism agent, 412–413
I
Iatrogenic botulism, 318
Immunization
for plague, 283–284
Immunofluorescence
in tularemia diagnosis, 302
Infant botulism, 317
Infection control
in anthrax prevention, 244–246
Infectious diseases bioterrorism agents causing surveillance of, 216–218
Influenza(s)
avian
as category C potential bioterrorism agent, 430–432
pandemics of
as category C potential bioterrorism agent, 430–432
Inhalational anthrax
victims of
recognition of, 234–236
Inhalational botulism, 317–318
J
Junin virus
clinical presentation and management of, 373–374
Justinian plague, 263–267
historical background of, 263
historical importance of, 266–267
infectious disease aspects of, 266
Procopius’ description of, 263–266
K
Kyasanur Forest disease virus and hemorrhagic fever
clinical presentation and management of, 383–384
L
Laboratory Response Network (LRN), 455, 468
Lassa fever
clinical presentation and management of, 370–373
virology and pathology of, 361–362
Listeria monocytogenes
as category B potential bioterrorism agent, 412
LRN. See Laboratory Response Network (LRN).
M
Machupovirus
clinical presentation and management of, 374
Marburg virus
clinical presentation and management of, 381
virology and pathology of, 366–367
Meningoencephalitis
hemorrhagic, 238–239
Microbial forensics, 455–473
described, 455–456
epidemiology studies in, 457–459
methods in, 461–468
non-nucleic acid–based methods, 466–468
nucleic acid–based methods, 462–466
national system for, 468
scenarios, 459–461
Microbiology
of anthrax, 231–234
Microsporidia
as category B potential bioterrorism agent, 413
Military Vaccination Program and Selective Civilian Vaccination Program for 2002–2004, 347
Model Act, 194–195
Model State Emergency Health Powers Act, 194–195
Monkeypox virus
as category C potential bioterrorism agent, 434–436

Mosquito-borne flavivirus hemorrhagic fevers
virology and pathology of, 367

Multidrug-resistant tuberculosis
as category C potential bioterrorism agent, 430

Myopericarditis
smallpox vaccination and, 346

Nairovirus genus
clinical presentation and management of, 376
virology and pathology of, 363–364

NASA–Goddard Space Flight Center, 196

National Center for Environmental Prediction, 196

National Institute of Allergy and Infectious Diseases (NIAID) Biodefense Research, 395

National Institutes of Health, 196

Neonate(s)
smallpox in, 340

New York City Board of Health, 347

Nipah virus
as category C potential bioterrorism agents, 423–424

Non-nucleic acid–based methods in medical forensics, 466–468

Noroviruses
as category B potential bioterrorism agent, 412

Nucleic acid–based methods in medical forensics

Ocular complications
smallpox vaccination and, 345
smallpox-related, 339–340

Oculoglandular tularemia, 299

Omsk hemorrhagic fever virus
clinical presentation and management of, 384
virology and pathology of, 369

Pneumonic plague, 256

Plague of Athens, 257–260
historical background of, 257–258
historical importance of, 260
infectious disease aspects of, 259–260
Thucydides description of, 258–259

Plague bacillus, 254

Plague of Athens, 257–260

Pirital virus
virology and pathology of, 361

Pneumonic plague, 256

Osteomyelitis
smallpox, 340
Polymerase chain reaction (PCR) in tularemia diagnosis, 301

Poxviridae, 329

Pregnancy smallpox during, 340 vaccinia in smallpox vaccination and, 346–347

Protein(s) SNARE, 314

Protozoa as category B potential bioterrorism agent, 413–414

Public health directors state and territorial, 197–206

Public Health Laboratories, 468

Public health laws in bioterrorism preparedness, 194–196

Public Health Security and Bioterrorism Preparedness and Response Act, 195

Public health system in bioterrorism preparedness, 188–190 emergency response capability in, 190 laboratory preparedness in, 190 recognition in, 188–189 training in, 188–189

Punta toro virus infection virology and pathology of, 363

R

Real-time Outbreak and Disease Surveillance (RODS) in syndromic surveillance of bioterrorism agents, 222–224

Respiratory tularemia, 301

Ricin as category B potential bioterrorism agent, 404–405

Rickettsia prowazkii as category B potential bioterrorism agent, 402–403

Rift Valley fever infection clinical presentation and management of, 375–376 virology and pathology of, 363

RODS. See Real-time Outbreak and Disease Surveillance (RODS).

S

Sabia virus clinical presentation and management of, 373

Salmonella sp as category B potential bioterrorism agent, 410–411

SARS. See Severe acute respiratory syndrome (SARS).

“Select Agent Program,” 195

Septicemic plague, 255–256

Severe acute respiratory syndrome (SARS) as category C potential bioterrorism agent, 432–433

Shigella sp as category B potential bioterrorism agent, 411


SNARE proteins, 314
Standardized Emergency Management System, 350–352
Staphylococcal enterotoxin B
as category B potential bioterrorism agent, 405–406
State Departments Bureau of Population, Refugees and Migration, 196

T
Tick-borne encephalitis complex
as category C potential bioterrorism agent, 427–428
Tick-borne flavivirus hemorrhagic fevers
virology and pathology of, 368–369
Tick-borne hemorrhagic fever viruses
as category C potential bioterrorism agent, 428–429
Tuberculosis
multidrug-resistant
as category C potential bioterrorism agent, 430
Tularemia, 289–311
as emerging disease, 294
clinical manifestations of, 297–300
diagnosis of, 300–302
culture in, 301
immunofluorescence in, 302
lymphocyte stimulation in, 301–302
PCR in, 301
serology in, 300–301
skin test in, 301
ecology of, 290–292
epidemiology of, 292–294
glandular, 297–299
historical background of, 289–290
ocular, 299
opharyngeal, 299
pathogenesis of, 295–297
prevention of, 304
respiratory, 301
routes of, 294–295
treatment of, 302–304
typhoidal, 299
ulceroglandular, 297–299
Typhoidal tularemia, 299–300

U
Ulceroglandular tularemia, 297–299
United States Army Medical Research Institute of Infectious Diseases, 359

US Defense Against Weapons of Mass Destruction Act, 195
US Department of Defense Global Emerging Infections Surveillance and Response System, 196
USAID, 196

V
Vaccination(s)
for smallpox complications of, 342–347
in anthrax prevention, 242–243
Vaccine(s)
for anthrax vaccines in development, 243–244
for smallpox, 347–348
Vaccine Adverse Event Reporting System, 347
Vaccinia
in pregnancy smallpox vaccination and, 346–347
Vaccinia necrosum–progressive vaccinia smallpox vaccination and, 344
Variola residua smallpox and, 339–340
Variola sine eruptione–variola sine exanthemata, 338–339
Varioleae vaccinae, 332
Variolation, 332
VENEZUELAN EQUINE ENCEPHALITIS (VEE).
Venezuelan equine encephalitis (VEE)
as category B potential bioterrorism agent, 406–408
Venezuelan hemorrhagic fever clinical presentation and management of, 373
Vireos chloerae
as category B potential bioterrorism agent, 411–412
Viral hemorrhagic fevers, 359–393
 Arenaviridae and clinical presentation and management of, 370–375
Arenaviruses and virology and pathology of, 360–362
We are unable to read the natural text from the provided image. If you have the natural text, please provide it, and we will be happy to help you with any questions you have.